Inventor · disambiguated record
Michael Boutros
Also filed as: BOUTROS MICHAEL
9 granted patents·11 pending applications·44 citations·filing 2006–2025
80Inventor score
Files withBOUTROS MICHAEL5DEUTSCHES KREBSFORSCH4DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS4IOMX THERAPEUTICS AG4BASILEA PHARMACEUTICA AG1
Top patents by PatentIndex Score
20 records- 0185US8629272B2Tricyclic pyrimidine derivatives as wnt antagonistsFUCHS FLORIAN·Filed 2010·Granted Jan 14, 2014·42 cites·19 claims
- 0281US9970938B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2016·Granted May 15, 2018·2 cites·60 claims
- 0364US11802285B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2019·Granted Oct 31, 2023·0 cites·10 claims
- 0464US2025340886A1Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0555US9994854B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2014·Granted Jun 12, 2018·0 cites·43 claims
- 0650US2018334442A1Chromene derivatives and their analogs as wnt pathway antagonistsDEUTSCHES KREBSFORSCH·Filed 2018·Application pending·0 cites
- 0749US2018298388A1Cytotoxic t cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2018·Application pending·0 cites
- 0848US12338440B2Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2018·Granted Jun 24, 2025·0 cites·33 claims
- 0946US10065939B2Chromene derivatives and their analogs as Wnt pathway antagonistsDEUTSCHES KREBSFORSCH·Filed 2016·Granted Sep 4, 2018·0 cites·8 claims
- 1044US10222377B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Mar 5, 2019·0 cites·61 claims
- 1142US9371333B2Chromene derivatives and their analoga as Wnt pathway antagonistsBOUTROS MICHAEL·Filed 2011·Granted Jun 21, 2016·0 cites·8 claims
- 1241US2023228760A1Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1341US2014329649A1Rehabilitation FlexorBOUTROS MICHAEL·Filed 2014·Application pending·0 cites
- 1438US2009186815A1Identification of jak/stat pathway modulating genes by genome wide rnai screeningBOUTROS MICHAEL·Filed 2006·Application pending·0 cites
- 1537US2019263906A1Immune modulators for reducing immune-resistance in melanoma and other proliferative diseasesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1636US2020164068A1Modulators of tumor immune resistance for the treatment of cancerDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1735US2020024347A1Or10h1 antigen binding proteins and uses thereofIOMX THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1833US9062114B2Gpr177 as target and marker in tumorsBOUTROS MICHAEL·Filed 2012·Granted Jun 23, 2015·0 cites·9 claims
- 1933US2019054110A1Modulators of ccr9 for treating tumor resistance to immune responsesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 2031US2013195884A1Novel modulators of trail signallingBOUTROS MICHAEL·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Boutros files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →